-
MDA Milestone: How ‘Fill the Boot’ Was Born
In 1952, a group of families affected by muscular dystrophy approached a Boston fire station
-
How We’re Changing the Narrative on Disability in Hollywood
For most of my life, I accepted stories about what it meant to be disabled.
-
Understanding Congenital Myasthenic Syndrome: Causes and Treatments
Congenital myasthenic syndrome (CMS) is a rare genetic condition that disrupts communication between nerves and
-
Motherhood, my life purpose, makes caregiving easier
It’s been a couple of weeks since my last column. I’ve missed writing them. I
-
Is Train Travel a Wheelchair-Friendly Alternative to Flying or Driving?
When the Zelaya family travels from their home in Brooklyn, New York, to Boston or
-
Accessible Travel on a Budget: Smart Tips for Exploring Affordably
Travel opens doors to new perspectives, cultures, and experiences. But for many, exploring the world
-
CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial
-
CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor to Advance Research and Improve Care for Individuals with Duchenne and Becker
Newport Beach, Calif., May 21, 2025 — CureDuchenne, a global nonprofit committed to finding and funding
-
Satellos reports data from their Phase 1b study
Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims
-
Satellos Announces Positive Functional Data from Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne
Satellos Bioscience Inc. has announced encouraging data from the company’s Phase 1b open-label study of
